PPARD and metabolic syndrome: In the same year, Billin wrote a review paper in which he summarized the general knowledge available at that time about PPAR-beta/delta agonists and properties in the treatment of dyslipidemia and type 2 diabetes, as well as emerging clinical data on various PPAR-beta/delta agonists.